Tag: RetinoStat Phase I

  • Oxford BioMedica, Sanofi Announce Interim Results For Wet AMD Drug

    (http://www.MacularDegenerations.com) Oxford BioMedica, the Oxford, England-based biopharmaceutical company developing gene-based medicines and therapeutic vaccines, and its partner Sanofi, the Paris, France-based diversified healthcare company, have announced a new development regarding testing of their age-related macular degeneration drug (AMD). In an 8 August press release, Oxford and Sanofi announced an encouraging interim assessment of their RetinoStat […]